HRT Insurance Coverage by State: A 2026 Guide for Menopause Care

HRT insurance coverage by state is one of the most confusing parts of starting menopause hormone therapy. Although the U.S. has a federal floor of coverage rules — including ACA essential health benefits and Medicare Part D drug formularies — the practical reality is that what a patient pays for estradiol, progesterone, or a telehealth menopause visit can swing by hundreds of dollars depending on the state, the payer, and the formulation. This 2026 guide explains how the federal-state-private layering works, where coverage is broadest, and how to talk to a clinician about options that fit a specific plan.

Key facts at a glance

• HRT insurance coverage by state depends on a three-layer system: federal ACA rules, state Medicaid formularies, and private commercial plan design.¹
• FDA-approved oral estradiol, estradiol patches, and oral micronized progesterone are covered by most Medicare Part D and ACA marketplace plans nationwide.²
• Compounded bioidentical hormone therapy is rarely covered by insurance in any state, regardless of payer.³
• 43 states plus DC have some form of telehealth parity law on the books as of 2026, making virtual menopause visits widely billable to commercial insurance.⁴

How HRT insurance coverage by state actually works

The short answer: there is no single federal rule that guarantees every U.S. resident the same HRT coverage. Instead, coverage emerges from three overlapping systems.

The first layer is the Affordable Care Act. ACA marketplace plans must cover ten categories of essential health benefits, which include prescription drugs, preventive services, and outpatient care. Menopause hormone therapy falls under the prescription-drug benefit, so virtually all marketplace plans in every state include some HRT options on their formulary.¹ The second layer is Medicaid, which is jointly funded by federal and state governments but administered state-by-state. Each state publishes its own preferred drug list (PDL), and the result is meaningful variation: a generic estradiol patch might sit on tier 1 in California's Medi-Cal program but require step therapy through oral estradiol first in another state's Medicaid program.² The third layer is private commercial insurance, where employer-sponsored and individual plans set their own formularies within federal and state guardrails.

The Kaiser Family Foundation reports that 41 states plus DC have adopted Medicaid expansion as of 2024, which generally correlates with broader preventive-service coverage including menopause care.⁵ Non-expansion states tend to have tighter formularies and stricter step-therapy rules. None of this means HRT is unavailable — it means the cash-vs-copay math is different by ZIP code.

What's typically covered: formulations, formularies, and tiers

Most commercial and Medicare Part D formularies in 2026 cover the following FDA-approved HRT products, though tier placement varies:

Estrogens

• Generic oral estradiol (1mg, 2mg tablets) — almost universally tier 1, typical copay $0-$15.²
• Generic estradiol transdermal patches (0.025mg, 0.05mg, 0.075mg, 0.1mg) — typically tier 1 or 2, copay $5-$40.
• Brand-name patches (Vivelle-Dot, Climara, Minivelle) — tier 2 or 3, copay $30-$90 with insurance; cash price $90-$180/month.⁶
• Estradiol vaginal cream, ring, or tablet (Estrace, Estring, Vagifem, Imvexxy) — typically covered for GSM/vulvovaginal atrophy indication; copays vary widely.

Progestogens

• Generic oral micronized progesterone (Prometrium generic, 100mg, 200mg) — typically tier 1, copay $0-$25.
• Brand Prometrium — tier 2-3, higher copay.
• Combination products (Bijuva, Combipatch) — often tier 3, may require prior authorization.

What's rarely covered

• Compounded bioidentical hormone therapy (cBHT) — pellets, custom creams, troches. The NAMS 2022 position statement and a 2020 National Academies report both note cBHT is generally not covered because compounded products are not FDA-approved as finished drugs.³
• Off-label testosterone for women — no FDA-approved female testosterone product exists in the U.S., so any testosterone prescription for menopausal women is off-label and rarely covered by commercial insurance.

A 2018 analysis published in Menopause found that out-of-pocket HRT costs varied 6-fold across U.S. metro areas, largely driven by formulary differences and pharmacy benefit manager contracts rather than the underlying drug cost.⁶

State-by-state coverage signals in 2026

Rather than listing all 50 states (formularies update quarterly), it's more useful to group states by coverage signals. Coverage strength here means consistent inclusion of FDA-approved estradiol and progesterone formulations across commercial, Medicaid, and marketplace plans, plus active telehealth parity.

Stronger coverage signals (typically broad formularies + telehealth parity): California, New York, Massachusetts, Washington, Oregon, Minnesota, Illinois, Maryland, New Jersey, Connecticut, Colorado, Vermont, Rhode Island, Hawaii, and DC. These jurisdictions tend to combine Medicaid expansion, parity laws, and active women's-health policy advocacy. The North American Menopause Society maintains a directory of certified menopause practitioners that is denser in these states, reflecting clinical infrastructure rather than coverage per se.¹

Mid-tier signals: Pennsylvania, Michigan, Ohio, Virginia, North Carolina, Arizona, Nevada, New Mexico, Maine, New Hampshire, Wisconsin, Iowa, Kentucky, Louisiana, and Indiana. These states have expanded Medicaid and have parity laws but show more formulary variability and higher prior-authorization rates on brand-name HRT.

Tighter coverage signals: Florida, Texas, Georgia, Tennessee, Alabama, Mississippi, South Carolina, Oklahoma, Kansas, Missouri, Wyoming, and South Dakota tend to have narrower Medicaid formularies, stricter step-therapy rules on brand-name patches, and fewer in-network NAMS-certified providers per capita. Generic estradiol and progesterone are still typically covered, but brand-name and combination products are more often cash-pay.

These groupings are directional and change as states update Medicaid PDLs and as commercial plans renegotiate PBM contracts. A patient should verify formulary status for their specific plan year.

Telehealth menopause provider options

Virtual menopause care has expanded rapidly because 43 states plus DC now have telehealth parity laws that require commercial insurers to reimburse virtual visits at parity with in-person visits.⁴ The following telehealth platforms differentiate on coverage model rather than ranking:

• Midi Health — accepts most major commercial insurance plans and Medicare Advantage in many states; NAMS-certified clinicians.
• Alloy — cash-pay subscription model with bundled prescription and shipping; predictable monthly cost regardless of state.
• Winona — cash-pay telehealth with compounded and FDA-approved HRT options; ships to most U.S. states.
• Evernow — telehealth menopause platform with async messaging-based care.

Coverage acceptance varies by state and by carrier, and any telehealth platform's in-network status can change quarterly. Verifying coverage before the first visit is reasonable. Discuss with a clinician whether an in-person or telehealth model fits both clinical needs and the realities of a specific insurance plan.

Safety, contraindications, and when to see a clinician

Insurance design should never be the primary driver of an HRT decision — clinical fit is. The NAMS 2022 position statement notes that hormone therapy is most favorable when initiated within 10 years of menopause onset or before age 60 in symptomatic women without contraindications.¹ ACOG's hormone-therapy guidance similarly emphasizes individualized risk-benefit assessment.⁷

Common contraindications to systemic HRT that any prescribing clinician will screen for include a history of estrogen-sensitive cancers, unexplained vaginal bleeding, active liver disease, history of stroke or venous thromboembolism, and uncontrolled hypertension. Anyone with these factors should discuss with a clinician whether non-hormonal options are more appropriate.

Patients should contact their clinician promptly about unexplained vaginal bleeding, severe headaches, chest pain, leg swelling, vision changes, or signs of a clot. The FDA's Menopause: Medicines to Help You consumer guide provides plain-language summaries of HRT risks and benefits and is a useful starting point for shared decision-making conversations.²

Cost and insurance considerations

Even within the same state, what a patient actually pays depends on plan deductible status, formulary tier, pharmacy choice, and whether the prescription is generic or brand. A few directional 2026 ranges:

• Generic oral estradiol with commercial insurance: $0-$15/month copay; cash with GoodRx $4-$15.⁶
• Generic estradiol patch with commercial insurance: $5-$40/month copay; cash with discount card $20-$60.
• Brand-name patch (Vivelle-Dot, Climara) with commercial insurance: $30-$90/month copay; cash $90-$180.
• Oral micronized progesterone generic with insurance: $0-$25/month copay; cash $15-$40.
• Compounded bioidenticals: cash only, typically $40-$120/month plus a separate clinician visit fee.³
• Telehealth menopause subscription bundles: $25-$110/month including visit + prescription, mostly cash-pay regardless of state.

Patients hitting prior-authorization denials for a preferred brand often have one of three paths: switch to a generic equivalent on the formulary, request a physician-led prior authorization, or use a manufacturer copay card on the brand-name product. None of these are universal solutions; what works depends on the specific plan and state.

Frequently asked questions

Does insurance cover HRT in every state in 2026?

Most commercial and ACA marketplace plans cover FDA-approved HRT in every state, but copays, prior authorization rules, and formulary tiers vary. Medicaid coverage varies more sharply — expansion states generally include estradiol and progesterone on preferred drug lists, while some non-expansion state formularies impose stricter step therapy.

Which states have the best HRT insurance coverage?

States with broad Medicaid expansion and active menopause-care advocacy — California, New York, Massachusetts, Washington, Oregon, Minnesota, and Illinois — tend to show the most consistent coverage of FDA-approved estradiol and progesterone formulations across commercial and public payers.

Are compounded bioidentical hormones covered by insurance anywhere?

Compounded bioidentical hormone therapy (cBHT) is rarely covered by any payer in any state because compounded products are not FDA-approved as finished drugs. The NAMS 2022 position statement and a 2020 National Academies report both note cBHT is generally a cash-pay product.

Does Medicare cover hormone therapy for menopause nationwide?

Medicare Part D plans cover most FDA-approved oral estradiol, estradiol patches, and oral micronized progesterone, with formulary tiers and copays varying by plan and region. Coverage rules are federal, but the specific plan options differ by state.

What is telehealth parity and how does it affect HRT visits?

Telehealth parity laws require insurers to reimburse virtual visits at the same rate as in-person visits. As of 2026, 43 states plus DC have some form of parity law on the books. This means a menopause telehealth visit is typically billable to commercial insurance the same way an office visit would be.

What should someone do if their state Medicaid does not cover their HRT prescription?

Discuss with a clinician whether an alternative formulation on the preferred drug list could work, or explore manufacturer copay cards, GoodRx/SingleCare discounts, or telehealth subscription bundles that include the prescription. Patient assistance programs can also help with brand-name products.

Sources

1. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. Menopause, 2022. https://pubmed.ncbi.nlm.nih.gov/35763600/
2. U.S. Food and Drug Administration. Menopause: Medicines to Help You. FDA Office of Women's Health, 2024. https://www.fda.gov/consumers/free-publications-women/menopause-medicines-help-you
3. National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy. National Academies Press, 2020. https://pubmed.ncbi.nlm.nih.gov/32833416/
4. Center for Connected Health Policy. State Telehealth Laws and Reimbursement Policies Report, Fall 2024. https://www.cchpca.org/2024/10/Fall2024_ExecutiveSummaryfinal.pdf
5. Kaiser Family Foundation. Status of State Medicaid Expansion Decisions, 2024 Update. https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions/
6. Pinkerton JV, et al. Cost of menopausal hormone therapy: paying out of pocket. Menopause, 2018. https://pubmed.ncbi.nlm.nih.gov/29381665/
7. ACOG Committee Opinion No. 565: Hormone Therapy and Heart Disease. Obstetrics & Gynecology, 2013 (reaffirmed 2023). https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/06/hormone-therapy-and-heart-disease
8. Centers for Medicare & Medicaid Services. Medicaid Drug Programs Data and Resources, 2024. https://www.medicaid.gov/medicaid/prescription-drugs/index.html

Related brands & guides

Updated May 30, 2026. Reviewed by Jane Smith, MD.